Country: United States
Language: English
Source: NLM (National Library of Medicine)
TERCONAZOLE (UNII: 0KJ2VE664U) (TERCONAZOLE - UNII:0KJ2VE664U)
PharmaDerm A division of Fougera Pharmaceuticals Inc.
TERCONAZOLE
TERCONAZOLE 4 mg in 1 g
PRESCRIPTION DRUG
Abbreviated New Drug Application
ZAZOLE- TERCONAZOLE CREAM PHARMADERM A DIVISION OF FOUGERA PHARMACEUTICALS INC. ---------- ZAZOLE VAGINAL CREAM 0.4% (TERCONAZOLE VAGINAL CREAM 0.4%) RX ONLY DESCRIPTION Zazole Vaginal Cream 0.4% (terconazole vaginal cream 0.4%) is a white to off-white, water washable cream for intravaginal administration containing 0.4% of the antifungal agent terconazole, _cis_-1-[_p_-[[2- (2,4-Dichlorophenyl)-2-(1-_H_-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4- isopropylpiperazine compounded in a cream base consisting of butylated hydroxyanisole, cetyl alcohol, isopropyl myristate, polysorbate 60, polysorbate 80, propylene glycol, stearyl alcohol, and purified water. The structural formula of terconazole is as follows: Terconazole, a triazole derivative, is a white to almost white powder with a molecular weight of 532.47. It is insoluble in water; sparingly soluble in ethanol; and soluble in butanol. CLINICAL PHARMACOLOGY Following intravaginal administration of terconazole in humans, absorption ranged from 5-8 % in three hysterectomized subjects and 12-16 % in two non-hysterectomized subjects with tubal ligations. Following oral (30 mg) administration of C-labelled terconazole, the harmonic half-life of elimination from the blood for the parent terconazole was 6.9 hours (range 4.0-11.3). Terconazole is extensively metabolized; the plasma AUC for terconazole compared to the AUC for total radioactivity was 0.6 %. Total radioactivity was eliminated from the blood with a harmonic half-life of 52.2 hours (range 44- 60). Excretion of radioactivity was both by renal (32-56 %) and fecal (47-52 %) routes. _In vitro_, terconazole is highly protein bound (94.9 %) and the degree of binding is independent of drug concentration. Photosensitivity reactions were observed in some normal volunteers following repeated dermal application of terconazole 2.0% and 0.8% creams under conditions of filtered artificial ultraviolet light. Photosensitivity reactions have not been observed in U.S. and foreign clinical trials in patients Read the complete document